Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial

BACKGROUND: There is no consensus on the therapeutic approach to ECOG 2 patients with locally advanced non-small-cell lung cancer (LA-NSCLC), despite the sizable percentage of these patients in clinical practice. This study focused on the efficacy, toxicity and the optimal chemotherapy regimen of CC...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Nan, Liu, Lipin, Liang, Jun, Wu, Shixiu, Chen, Ming, Lv, Changxing, Zhao, Lujun, Shi, Anhui, Jiang, Wei, Xu, Yaping, Zhou, Zongmei, Wang, Jingbo, Wang, Wenqing, Chen, Dongfu, Hui, Zhouguang, Lv, Jima, Zhang, Hongxing, Feng, Qinfu, Xiao, Zefen, Wang, Xin, Zhang, Tao, Yin, Weibo, Li, Junling, He, Jie, Wang, Luhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137304/
https://www.ncbi.nlm.nih.gov/pubmed/32252680
http://dx.doi.org/10.1186/s12885-020-06780-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137304/
https://www.ncbi.nlm.nih.gov/pubmed/32252680
http://dx.doi.org/10.1186/s12885-020-06780-x

Ejemplares similares